Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IP Irinotecan + CAPOX in Gastric Cancer with Peritoneal Carcinomatosis
NCT05379790Phase 1Completed
- Sponsor
- Erasmus MC
- Start
- May 2022
- Primary completion
- Nov 2024
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in gastric cancer (GC) (6 arms), sponsored by Erasmus MC. Primary endpoint: Maximum-tolerated dose at 18 weeks. Started May 2022; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05379790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05379790.